<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160896</url>
  </required_header>
  <id_info>
    <org_study_id>SALIRI-2021</org_study_id>
    <nct_id>NCT05160896</nct_id>
  </id_info>
  <brief_title>SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer</brief_title>
  <official_title>Raltitrexed Combined With Irinotecan (SALIRI) Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer (mCRC) : an Open-label, Multi-center, and Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to investigate the efficacy and safety of raltitrexed combined with&#xD;
      Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal&#xD;
      cancer(mCRC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of previous studies show that raltitrexed combined with oxaliplatin/irinotecan as&#xD;
      first-line treatment for advanced metastatic colorectal cancer(mCRC) is safe and effective.&#xD;
      Chinese registered clinical studies show that raltitrexed combined with oxaliplatin has&#xD;
      better safety and overall clinical efficacy than 5-FU combined with oxaliplatin in the&#xD;
      treatment of mCRC. However, there is no study data on raltitrexed plus irinotecan (SALIRI)&#xD;
      combined with targeted drugs as first-line treatment for mCRC in Chinese patients. This an&#xD;
      open-label, multi-center, and prospective phase Ⅱ study enroled mCRC patients treated with&#xD;
      first-line raltitrexed plus Irinotecan (SALIRI) based chemotherapy. Plan to to enroll 90&#xD;
      patients. The primary outcome is Overall Response Rate(ORR). The secondary Outcomes are&#xD;
      Progression Free Survival (PFS)，Overall Survival (OS)，disease control rate (DCR)，the&#xD;
      occurrence of adverse reactions(AEs)，and Quality of Life [WHO-QOL].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>(overall response rate) measured in percentage of all treated patients according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>24 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO-QOL</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>24 months</time_frame>
    <description>the occurrence of adverse reactions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>MSS or MSI-L/pMMR, RAS and BRAF are both wild type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the primary lesion is located in the left colorectal:&#xD;
SALIRI plus cetuximab&#xD;
One cycle (cycle duration 14 days) consists of:&#xD;
Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 cetuximab 500 mg/ m² , iv, day 1&#xD;
the primary lesion is located in the right colorectal:&#xD;
SALIRI plus bevacizumab&#xD;
One cycle (cycle duration 14 days) consists of:&#xD;
Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 Bevacizumab 5 mg/kg, iv, day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Raltitrexed 2 mg/m² iv, 15min. day 1</description>
    <arm_group_label>MSS or MSI-L/pMMR, RAS and BRAF are both wild type</arm_group_label>
    <other_name>Sai Wei Jian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m² iv, 30 - 90 min. day 1</description>
    <arm_group_label>MSS or MSI-L/pMMR, RAS and BRAF are both wild type</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 5 mg/kg, iv, day 1</description>
    <arm_group_label>MSS or MSI-L/pMMR, RAS and BRAF are both wild type</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>cetuximab 500 mg/ m² , iv, day 1</description>
    <arm_group_label>MSS or MSI-L/pMMR, RAS and BRAF are both wild type</arm_group_label>
    <other_name>ERBITUX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-75 years old.&#xD;
&#xD;
          2. Life expectancy ≥ 3 months.&#xD;
&#xD;
          3. Patients with unresectable advanced colorectal cancer confirmed by histology or&#xD;
             cytology.&#xD;
&#xD;
          4. Patients with initially treated metastatic colorectal cancer who were assessed to be&#xD;
             unable to undergo radical surgery，or recurrence and metastasis more than 6 months&#xD;
             after receiving radical surgery adjuvant chemotherapy, and the metastases can not be&#xD;
             removed.&#xD;
&#xD;
          5. At least one measurable lesion by CT or MRI according to RECIST1.1 criteria.&#xD;
&#xD;
          6. ECOG 0 ~ 1.&#xD;
&#xD;
          7. The major organs were functioning normally, and the laboratory examination results&#xD;
             within 1 week met the following conditions before enrollment: ①Absolute neutrophil&#xD;
             count (ANC)≥1.5×109/L ②Platelet count（PLT）≥90.0 × 109/L ③Hemoglobin concentration（HB）&#xD;
             ≥90g/L④ Total bilirubin（TBI）≤1.5×ULN ⑤ Serum creatinine （Cr）≤l.5×ULN ，Endogenous&#xD;
             creatinine clearance &gt;60ml/min（Cockcroft-Gault Formula ）⑥Aspartate aminotransferase&#xD;
             (AST), Alanine aminotransferase (ALT), Alkaline phosphatase(AP): ≤2.5 ×ULN (≤5 ×ULN&#xD;
             for metastases to liver).&#xD;
&#xD;
          8. Women of child-bearing age must undergo a pregnancy test within 7 days prior to&#xD;
             enrollment and have a negative result, and are willing to use an appropriate method of&#xD;
             contraception during the trial and within 6 months after the last trial drug is given.&#xD;
             For men who agree to use an appropriate method of contraception during the trial and&#xD;
             up to six months after the last administration of the trial drug.&#xD;
&#xD;
          9. Sign the informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to any research drug and its excipients.&#xD;
&#xD;
          2. There is a history of brain metastases, uncontrolled spinal cord compression, or&#xD;
             cancerous meningitis, or newly discovered evidence of brain or Pia Mater Disease.&#xD;
&#xD;
          3. History of other malignancies, except cured Basal cell or squamous Cell Carcinoma of&#xD;
             the skin and carcinoma in situ of the cervix.&#xD;
&#xD;
          4. Participate in another clinical trial within 30 days prior to admission and receive a&#xD;
             research drug and any concomitant therapy containing a research drug.&#xD;
&#xD;
          5. Any of the following events occurred during the first 6 months in Group A:&#xD;
             cerebrovascular accident (including stroke or transient ischemic attack) , myocardial&#xD;
             infarction, severe/unstable angina, coronary/peripheral artery bypass graft, and&#xD;
             congestive heart failure NYHA Grade III or IV, drug-treated or clinically significant&#xD;
             Arrhythmia, prolonged Q-T interval of ECG, etc.&#xD;
&#xD;
          6. Bowel obstruction or incomplete bowel obstruction, history of inflammatory bowel&#xD;
             disease or extensive Colectomy, 50% or extensive small bowel resection with chronic&#xD;
             diarrhea.&#xD;
&#xD;
          7. The presence of an active infection or a concomitant disease that seriously endangers&#xD;
             the patient's safety or affects the patient's ability to complete the study.&#xD;
&#xD;
          8. Other conditions that the researchers think should be ruled out.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Yuan, Ph.D&amp;MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Yuan, Ph.D&amp;MD</last_name>
    <phone>13858193601</phone>
    <email>yuanying1999@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Medical College of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Yuan</last_name>
      <phone>13858193601</phone>
      <email>yuanying1999@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ying Yuan, Ph.D &amp; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>raltitrexed</keyword>
  <keyword>irinotecan</keyword>
  <keyword>first-line Treatment</keyword>
  <keyword>Advanced Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

